1. 1401 Metronomic topotecan causes a favorable type of therapy-inducedsenescence and prolongs survival in MYCN amplified neuroblastoma xenografts. (September 2015) Authors: Taschner-Mandl, S.; Schwarz, M.; Blaha, J.; Kauer, M.; Kromp, F.; Frank, N.; Rifatbegovic, F.; Weiss, T.; Ladenstein, R.; Hohenegger, M.; Ambros, I.; Ambros, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S198 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1407 The European Strategic Plan for children and adolescents with cancer. (September 2015) Authors: Vassal, G.; Schrappe, M.; Pritchard-Jones, K.; Arnold, F.; Basset, L.; Biondi, A.; Bode, G.; Eggert, A.; Hjorth, L.; Kamerić, L.; Karner, S.; Kearns, P.; Kienesberger, A.; Kowalczyk, J.; Lack, P.; Perilongo, G.; Sullivan, R.; Tsirou, A.; Kamerić, N.; Essiaf, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S200 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 234 Genomic analyses of disseminated neuroblastoma cells to study tumor evolution and prognostic markers. (September 2015) Authors: Abbasi, M.R.; Rifatbegovic, F.; Brunner, C.; Ladenstein, R.; Ambros, I.M.; Ambros, P.F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 235 Genomic analyses of circulating tumor DNA in the plasma of neuroblastoma patients. (September 2015) Authors: Huetter, S.C.; Walder, D.; Brunner, C.; Ladenstein, R.; Abbasi, M.R.; Ambros, I.M.; Ambros, P.F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Biosynthesis of Riboflavin: Structure and mechanism of lumazine synthase. (February 1996) Authors: Bacher, A.; Fischer, M.; Kis, K.; Kugelbrey, K.; Mörtl, S.; Scheuring, J.; Weinkauf, S.; Eberhardt, S.; Schmidt-Bäse, K.; Huber, R.; Ritsert, K.; Cushman, M.; Ladenstein, R. Journal: Biochemical Society transactions Issue: Volume 24:Number 1(1996) Page Start: 89 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience. (February 2021) Authors: Berlanga, P.; Pasqualini, C.; Pötschger, U.; Sangüesa, C.; Castellani, M.R.; Cañete, A.; Luksch, R.; Elliot, M.; Schreier, G.; Kropf, M.; Morgenstern, D.; Papadakis, V.; Ash, S.; Ruud, E.; Brock, P.; Wieczorek, A.; Kogner, P.; Trahair, T.; Ambros, P.; Boterberg, T. Journal: European journal of cancer Issue: Volume 144(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re‐evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. Issue 1 (4th November 2018) Authors: Duong, J.K.; Veal, G.J.; Nath, C.E.; Shaw, P.J.; Errington, J.; Ladenstein, R.; Boddy, A.V. Journal: British journal of clinical pharmacology Issue: Volume 85:Issue 1(2019) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗